| SVRA |
Savara Inc. |
Common Stock, par value $0.001 per share |
9.9% |
$123,617,225 |
+$48,545,450 |
20,881,288 |
+65% |
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2025 |
| ORKA |
ORUKA THERAPEUTICS, INC. |
Common Stock, par value $0.001 per share |
9.9% |
$94,411,973 |
+$14,637,703 |
4,909,619 |
+18% |
Venrock Healthcare Capital Partners III, L.P. |
30 Sep 2025 |
| JBIO |
JADE BIOSCIENCES, INC. |
Common Stock, $0.0001 par value |
9.9% |
$70,905,847 |
+$26,271,533 |
5,115,862 |
+59% |
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2025 |
| CYBN |
Cybin Inc. |
Common Shares, no par value |
9.9% |
$30,106,217 |
|
5,111,412 |
|
Venrock Healthcare Capital Partners III, L.P. |
31 Oct 2025 |
| VOR |
VOR BIOPHARMA INC. |
Common Stock, $0.0001 par value per share |
9.9% |
$30,049,977 |
+$19,734,899 |
2,216,075 |
+191% |
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2025 |
| KRRO |
Korro Bio, Inc. |
Common Stock, par value $0.001 per share |
9.9% |
$17,760,012 |
|
1,488,685 |
|
Venrock Healthcare Capital Partners III, L.P. |
10 Mar 2026 |
| TENX |
Tenax Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
9.9% |
$10,429,033 |
+$2,106,834 |
692,959 |
+25% |
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2025 |
| SRZN |
Surrozen, Inc. |
Common Stock, $0.0001 par value per share |
9.9% |
$8,742,911 |
|
872,546 |
|
Venrock Healthcare Capital Partners III, L.P. |
26 Mar 2025 |
| ZURA |
ZURA BIO LIMITED |
Class A Ordinary Shares, par value $0.0001 per share |
9.9% |
$8,322,892 |
-$888,073 |
6,353,353 |
-9.6% |
Venrock Healthcare Capital Partners III, L.P. |
30 Jun 2025 |
| GLYC |
Crescent Biopharma, Inc. |
Ordinary Shares, $0.001 par value per share |
9.9% |
|
|
1,391,196 |
|
Venrock Healthcare Capital Partners III, L.P. |
13 Jun 2025 |
| CBIO |
Crescent Biopharma, Inc. |
Ordinary Shares, $0.001 par value per share |
9.5% |
$29,460,007 |
|
2,666,064 |
|
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2025 |
| CTMX |
CytomX Therapeutics, Inc. |
Common Stock, $0.00001 par value per share |
9.4% |
$49,641,185 |
+$8,195,110 |
15,561,500 |
+20% |
Venrock Healthcare Capital Partners III, L.P. |
30 Sep 2025 |
| CASI |
CASI Pharmaceuticals, Inc. |
Ordinary shares, par value US$0.0001 |
9.2% |
$2,066,749 |
|
1,987,259 |
|
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2025 |
| ENGN |
enGene Holdings Inc. |
Common Shares |
7.1% |
$39,984,449 |
-$2,304,500 |
4,771,414 |
-5.4% |
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2025 |
| IPSC |
Century Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
7.1% |
$12,354,782 |
+$8,606,536 |
13,043,478 |
+230% |
Venrock Healthcare Capital Partners III, L.P. |
09 Jan 2026 |
| ANL |
Adlai Nortye Ltd. |
Ordinary Shares, $0.001 par value per share |
6.1% |
$15,710,255 |
|
9,638,193 |
|
Venrock Healthcare Capital Partners III, L.P. |
04 Feb 2026 |
| GLTO |
Galecto, Inc. |
Common Stock, $0.00001 par value per share |
6% |
$78,630,443 |
|
3,603,595 |
|
Venrock Healthcare Capital Partners III, L.P. |
09 Feb 2026 |
| ORIC |
ORIC Pharmaceuticals, Inc. |
Common Stock, par value $0.0001 per share |
5.8% |
$57,556,972 |
-$9,335,442 |
5,676,230 |
-14% |
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2025 |
| ELVN |
ENLIVEN THERAPEUTICS, INC. |
Common Stock, $0.001 par value per share |
5.4% |
$66,042,996 |
|
3,226,331 |
|
Venrock Healthcare Capital Partners III, L.P. |
30 Sep 2025 |
| PRAX |
Praxis Precision Medicines, Inc. |
Common Stock, par value $0.0001 per share |
4.9% |
$37,813,688 |
-$6,466,960 |
1,016,497 |
-15% |
Venrock Healthcare Capital Partners III, L.P. |
31 Mar 2025 |
| SYRE |
Spyre Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
4.6% |
$40,335,429 |
|
2,685,448 |
|
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2024 |
| VRDN |
Viridian Therapeutics, Inc. |
Common Stock, $0.01 par value per share |
4.5% |
$48,373,931 |
|
3,575,309 |
|
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2024 |
| ATXS |
Astria Therapeutics, Inc. |
Common Stock, $0.001 par value per share |
4.4% |
$12,704,489 |
|
2,457,348 |
|
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2024 |
| APLT |
Applied Therapeutics, Inc. |
Common Stock $0.0001 par value per share |
4.1% |
$2,171,407 |
-$2,432,661 |
5,567,709 |
-53% |
Venrock Healthcare Capital Partners III, L.P. |
31 Mar 2025 |
| PHVS |
Pharvaris N.V. |
Ordinary shares, par value EURO0.12 per share |
3.8% |
$51,436,214 |
|
2,047,620 |
|
Venrock Healthcare Capital Partners III, L.P. |
30 Jun 2025 |
| OCUL |
Ocular Therapeutix Inc |
Common Stock, $0.0001 par value per share |
3.2% |
$81,120,329 |
-$71,516,295 |
6,862,972 |
-47% |
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2025 |
| CDTX |
CIDARA THERAPEUTICS, INC. |
Common Stock, par value $0.0001 per share |
3.2% |
$32,299,508 |
-$23,243,750 |
639,088 |
-42% |
Venrock Healthcare Capital Partners III, L.P. |
30 Jun 2025 |
| DNTH |
Dianthus Therapeutics, Inc. |
Common Stock, $0.001 par value per share |
3.1% |
$20,060,000 |
|
1,000,000 |
|
Venrock Healthcare Capital Partners III, L.P. |
30 Jun 2025 |
| AQST |
Aquestive Therapeutics, Inc. |
Common stock, $0.001 par value per share |
2.9% |
$7,494,890 |
|
2,629,786 |
|
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2024 |
| MRSN |
MERSANA THERAPEUTICS, INC. |
Common Stock, $0.0001 par value per share |
2.9% |
$1,286,757 |
-$2,406,047 |
3,574,325 |
-65% |
Venrock Healthcare Capital Partners III, L.P. |
31 Mar 2025 |
| FDMT |
4D MOLECULAR THERAPEUTICS, INC. |
Common Stock, par value $0.0001 per share |
1.5% |
$2,202,200 |
-$7,393,006 |
677,600 |
-77% |
Venrock Healthcare Capital Partners III, L.P. |
31 Mar 2025 |
| ABVX |
Abivax SA |
Ordinary Shares, nominal value 0.01 euro per share |
0.8% |
$48,964,292 |
|
576,729 |
|
Venrock Healthcare Capital Partners III, L.P. |
30 Sep 2025 |
| PCSC |
Perceptive Capital Solutions Corp |
Class A Ordinary Shares, par value $0.0001 per share |
0% |
$0 |
|
0 |
|
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2025 |
| ADVM |
ADVERUM BIOTECHNOLOGIES, INC. |
Common Stock, $0.0001 par value |
0% |
$0 |
|
0 |
|
Venrock Healthcare Capital Partners III, L.P. |
31 Dec 2024 |